Mannatech Receives Buy Rating from StockNews.com Analysts

On a recent Friday, analytical service StockNews.com commenced coverage on Mannatech, a publically traded health and wellness company bearing the NASDAQ ticker MTEX. The company garnered a positive assessment with the issuance of a buy rating for their stock, signaling potential growth and investment interest.

Mannatech Stock Performance

Trading opened at $8.11 on the reporting Friday. Throughout the past fifty-two weeks, Mannatech's stock fluctuated between a low of $7.50 and a peak of $21.23. The stock's average price over the past 50 days stood at $8.64, while the 200-day average was noted at $10.28. Regarding financial stability, Mannatech exhibits a current ratio of 1.09, a quick ratio of 0.50, and a debt-to-equity ratio of a modest 0.10.

The last quarter's earnings report, released on November 7th, revealed the company's earnings per share (EPS) at $0.01. Despite this, the company experienced a net margin decline of 5.62% and a sharp drop in return on equity of 59.58%. Revenue for the quarter was reported at $32.55 million.

Institutional Investors Weigh In On Mannatech

Hedge fund activities show increasing interest in MTEX shares. In the first quarter, Tower Research Capital LLC TRC augmented its stake in Mannatech by 167.9%, resulting in ownership of 1,575 shares post-acquisition of an additional 987 shares. This stake, valued at approximately $27,000, accounted for about 0.08% of Mannatech, as per SEC filings. Collectively, institutional investors hold 24.31% of the company's shares.

About Mannatech

Mannatech functions internationally, focusing on the health and wellness sector. Their product development, marketing, and sales operations include nutritional supplements, topical and skin care products, anti-aging treatments, as well as weight-management and fitness products. Mannatech sells its products through direct selling, e-commerce, and network marketing channels.

Mannatech, StockNews, Coverage